<DOC>
	<DOC>NCT01128153</DOC>
	<brief_summary>The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes and will be well tolerated.</brief_summary>
	<brief_title>Saxagliptin Triple Oral Therapy</brief_title>
	<detailed_description>A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination with Metformin and Sulfonylurea in Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control with Combination of Metformin and Sulfonylurea</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Written Informed Consent Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c &gt; or = 7% and &lt; or = 10%) despite being on combination of metformin and sulfonylurea for at least 8 weeks prior to Visit 1 BMI &lt; or = 40 kg/m2 Symptoms of poorly controlled diabetes including but not limited to marked polyuria and marked polydipsia with &gt; 10% weight loss in 3 months prior to entry, or other signs and symptoms History of diabetic ketoacidosis or hyperosmolar nonketotic coma Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP1 analogues, and/or other oral antidiabetic agents (other than metformin or sulfonylurea) Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor Estimated CrCl &lt; 60 ml/min at Visit 2 CHF (NYHA class III or IV) and/or LVEF &lt;40% Active liver disease and/or significant abnormal liver function defined as AST and/or ALT &gt; 3 x ULN and/or bilirubin &gt; 2.0 mg/dL at Visit 2. Creatine kinase &gt; or = 10 x ULN at Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Inadequate Glycaemic Control</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Sulfonylurea</keyword>
	<keyword>Triple Oral Therapy</keyword>
</DOC>